26 / 38
•
The post-approval safety, tolerability and effectiveness of nal-IRI+5-FU/LV in advanced PDAC
patients was assessed at a single centre*
•
A retrospective chart review of all patients who began treatment with nal-IRI+5-FU/LV from
October 2015 through June 2017 was conducted
–
All AEs and SAEs were graded per NCI-CTCAE V4.0
–
Patients were assessed every 8-12 weeks by CT
–
Disease response was assessed using RECIST version 1.1 criteria
•
Patients without progression or death were censored at the last follow-up date November
2
nd
, 2017
Nanoliposomal irinotecan with fluorouracil for the treatment of
advanced pancreatic cancer
*
Memorial Sloan Kettering Cancer Center
AE, adverse event; CT, computed tomography; NCI-CTCAE, National Cancer
Institute Common Terminology Criteria for Adverse Events, SAE, serious AE
Glassman DC, et al. J Clin Oncol 2018;
36 (suppl 4S): 471 (and poster)
•
Patients without disease progression on prior irinotecan-based therapy fared significantly
better than patients with progression, when treated with nal-IRI+5-FU/LV
•
Sequential therapy with gemcitabine+nab-paclitaxel followed by nal-IRI+5-FU/LV shows
promising median overall disease survival
•
The study results support the efficacy and safety of nal-IRI+5-FU/LV in the therapy of
advanced PDAC